The Life Sciences team advised Zafgen, Inc. (Nasdaq:ZFGN) on its reverse merger with Chondrial Therapeutics, Inc. The combined, publicly traded clinical-stage biotechnology company operates under the name Larimar Therapeutics, Inc., and its shares commenced trading on the Nasdaq Global Market on May 29, 2020, under the ticker symbol "LRMR."
Larimar is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company's lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich's ataxia, a rare and progressive genetic disease.
The Goodwin team was led by Andrew Goodman, Danielle Lauzon, Mitchell Bloom, Tevia Pollard, and Joshua Tarr, and included Sarah Bock, Morgan Frisoli, Jennifer Fay, Caroline Galiatsos, Theresa Kavanaugh, Megan Gustafson, Ginggi Storer, Steven Tjoe, Roger Cohen, Deborah Birnbach, Jennifer Luz, Janet Andolina and Nicole Spiteri.
For more details, read the press release and article in The Wall Street Journal.